At a Glance
| Property | Detail |
|---|---|
| What it is | Glycyl-L-histidyl-L-lysine bound to copper; a naturally occurring tripeptide sold widely as a cosmetic ingredient [1][2] |
| Evidence Level | Low for topical (small cosmetic studies; the one randomized trial verified found no objective benefit [5]); no published trials for injection |
| Topical Dose | 1-2% concentration in serum or cream, twice daily |
| Subcutaneous Dose | 1-2 mg (most commonly 2 mg), once daily or 3-5x weekly |
| Microneedling Adjunct | 0.5-1% solution after in-clinic microneedling; home users report 1-2% |
| Onset of Results (Topical) | 8-12 weeks for visible anti-aging effects |
| Key Consideration | Formulation quality and stability critical for efficacy |
| Approval status | Not an approved medicine (FDA, EMA, BfArM). Topical products are sold as cosmetics |
| Anti-doping (WADA 2026) | Not named. Injectable use of an unapproved substance may fall under S0; athletes should check with their anti-doping organisation |
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. Basis: Trial (published human study, PMID), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only).
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Facial skin ageing | 1-2% serum or cream (compilations range from 0.5% to 3%) | Topical | Once or twice daily | 8-12 weeks, often continued | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Hair thinning | 1-2% solution | Topical, massaged into the scalp | Once daily | 12 weeks minimum; 3-6 months to judge | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Systemic or “whole-body” use | 1-2 mg, most commonly 2 mg (Peptide DB lists up to 3 mg) | SC | Once daily or 3-5 times weekly | 4-8 weeks on, 2-4 weeks off | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| With microneedling | 1-2% solution | Topical, straight after needling | With each session, 1-2 times weekly | 8-12 weeks | Anecdotal (Peptide Protocol Wiki) |
| Minor wounds and scars | 1-2% gel | Topical | 2-3 times daily | Until healed | Anecdotal (Peptide DB) |
| Combined with BPC-157 or TB-500 for repair | GHK-Cu as above + BPC-157 250-500 mcg daily or TB-500 per its protocol | SC or topical | As listed | 4-8 weeks | Anecdotal (Peptide Protocol Wiki) |
| Skin care after CO2 laser resurfacing | Commercial GHK-Cu skin-care products (concentration not given in the abstract) | Topical | Post-procedure regimen | 12 weeks | Trial (randomised, 13 completers; no objective difference from the same regimen without GHK-Cu; PMID 16847171) |
The only randomised human study found here measured no objective benefit, and no published trial has tested injected GHK-Cu at any dose. The topical concentrations come from cosmetic formulation practice, the injected doses from community use.
Technique, reconstitution and storage are in the peptide injection guide.
What GHK-Cu Is and What It Does
GHK is a three-amino-acid peptide (glycine, histidine, lysine) with a strong affinity for copper. It was first found in human plasma, and levels appear to fall with age [1]. Bound to copper, it can deliver the metal to enzymes that need it, including lysyl oxidase, which cross-links collagen and elastin.
In cell culture, GHK-Cu increases collagen synthesis by fibroblasts [3]. Gene-expression analyses by Pickart’s group report that GHK shifts the activity of many genes linked to tissue repair, antioxidant defence and inflammation [2][4]. Those are interesting findings, but they come from cell and computational data. A gene signature in a dish is a hypothesis about what might happen in skin, not evidence that it does.
What the Evidence Shows
Preclinical
Laboratory and animal work makes up most of the literature: collagen stimulation in fibroblast cultures [3], wound-healing effects in animal models and broad gene-expression changes [2][4].
Human
| Study | Design | n | What was studied | Finding | Certainty |
|---|---|---|---|---|---|
| Miller et al. 2006 [5] | Randomized, blinded evaluators, after CO2 laser resurfacing | 13 completed | Skincare regimen with vs without GHK-Cu | No difference in redness resolution, wrinkles or overall skin quality on objective assessment; patient-reported satisfaction higher with GHK-Cu | Low (very small) |
| Cosmetic studies summarised in reviews [1][4] | Mostly small, often manufacturer-linked | Small | Creams and serums | Reported improvements in wrinkles, firmness or density | Very low to low |
| Injectable GHK-Cu | No published trials found | 0 | None | None | No evidence |
The honest summary: GHK-Cu skincare is plausible and probably safe for most people, but the controlled evidence that it outperforms a good basic routine (sunscreen, a retinoid where tolerated, moisturiser) is weak. For injection there is no published human trial.
How Do You Dose GHK-Cu?
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
The answer depends entirely on what you are trying to achieve and which route of administration you are using. GHK-Cu is unusual among peptides in that topical application — the most accessible route — also has the strongest evidence base. Most peptides require injection to achieve meaningful tissue concentrations. GHK-Cu’s small molecular size (tripeptide, molecular weight ~403 Da) allows meaningful skin penetration, particularly with properly formulated delivery vehicles.
Here is what the evidence supports for each route, where the evidence is thin, and how dosing is approached in practice.
Topical Dosing
Why Topical Works for GHK-Cu
Most peptides are too large to penetrate the skin barrier effectively. GHK-Cu is an exception for several reasons:
-
Small size. At only three amino acids (Gly-His-Lys) plus a copper ion, GHK-Cu has a molecular weight of approximately 403 Da — below the approximate 500 Da threshold generally considered the upper limit for passive skin penetration [6]. How much reaches the dermis from a given product is not well measured.
-
Charge characteristics. The copper binding modifies the peptide’s interaction with the lipid-rich stratum corneum in ways that may facilitate penetration.
-
Target tissue is the destination. Unlike peptides that must reach distant tissues, GHK-Cu’s target for anti-aging — dermal fibroblasts — sits directly beneath the skin surface. Even modest penetration delivers the peptide to its site of action.
Standard Topical Protocol
| Parameter | Detail |
|---|---|
| Concentration | 1-2% GHK-Cu |
| Formulation | Serum (preferred for penetration) or cream |
| Application | Twice daily — morning and evening |
| Application area | Clean, dry skin; face, neck, decolletage, or hands |
| Amount | 2-4 drops (serum) or pea-sized amount (cream) per area |
| Layering order | After cleansing and toner, before heavier moisturizers and sunscreen |
| Expected onset | Subtle improvement at 4-6 weeks; measurable results at 8-12 weeks |
| Duration | Continuous use recommended |
Concentration Matters
The cosmetic studies that reported wrinkle reduction and skin density improvement used GHK-Cu at 1-2% concentrations; they are small and often manufacturer-linked [1][4]. Below 0.5%, the evidence for meaningful anti-aging effects becomes questionable. Many consumer products contain copper peptides at undisclosed or subtherapeutic concentrations — this is one of the reasons that product selection matters as much as the peptide itself.
| Concentration | Expected Efficacy | Clinical Evidence |
|---|---|---|
| Below 0.5% | Unlikely to produce measurable anti-aging effects | Insufficient |
| 0.5-1% | Mild improvement possible | Limited |
| 1-2% | Range used in cosmetic studies reporting wrinkle/density improvement | Low (small studies) |
| Above 2% | Not demonstrated to be more effective; may increase irritation risk | Insufficient |
Formulation Stability
GHK-Cu has specific formulation requirements that affect its stability and therefore its efficacy:
- pH sensitivity. Optimal stability at pH 5.5-6.5, which is close to physiological skin pH. Formulations outside this range may degrade the peptide or release the copper ion.
- Oxidation susceptibility. Copper can catalyze oxidation reactions. Formulations should include appropriate antioxidant stabilizers and use airless pump packaging to minimize air exposure.
- Light sensitivity. UV exposure can degrade GHK-Cu. Amber or opaque packaging is preferred.
- Interaction with other actives. Vitamin C (L-ascorbic acid) at low pH can interact with copper, potentially causing oxidation of the vitamin C and destabilization of the GHK-Cu complex. If using both, apply at different times or separate by at least 30 minutes.
Subcutaneous Injection Dosing
Injectable GHK-Cu is used by some clinicians for systemic effects — not limited to skin, but including systemic tissue repair, anti-inflammatory effects, and the broad gene expression modulation that GHK-Cu is known for.
Standard Injection Protocol
| Parameter | Detail |
|---|---|
| Dose | 1-2 mg per injection, most commonly 2 mg (Peptide DB lists up to 3 mg) |
| Frequency | Once daily or 3-5 times per week |
| Route | Subcutaneous |
| Injection site | Abdominal fat, upper arm, or anterior thigh |
| Cycle length | 4-8 weeks |
| Rest period | 2-4 weeks between cycles |
| Basis | Practice protocol (see the protocol table above) |
Evidence Basis for Injectable Dosing
Let me be transparent: the evidence for injectable GHK-Cu dosing in humans is limited. The 1-2 mg dose range is extrapolated from preclinical studies showing biological activity at micromolar concentrations in tissue cultures, scaled to estimated systemic distribution. No formal human pharmacokinetic studies of subcutaneous GHK-Cu have been published.
This places injectable GHK-Cu dosing in the same category as BPC-157 peptide therapy and TB-500 tissue repair peptide dosing — educated extrapolation, not validated pharmacology. The topical route has substantially more clinical evidence and should be preferred when the target is skin.
When Injectable May Be Preferred
| Goal | Route | Rationale |
|---|---|---|
| Facial anti-aging | Topical | Most evidence; direct delivery to target |
| Systemic anti-inflammatory | Injectable | Systemic distribution needed |
| Gene expression modulation (systemic) | Injectable | Topical delivery limited to application site |
| Post-surgical wound healing | Topical + injectable | Combined approach for local and systemic effects |
| Hair regrowth (scalp) | Topical to scalp or mesotherapy | Direct follicle delivery |
Microneedling-Enhanced Delivery
Microneedling creates microchannels in the skin that substantially increase peptide penetration into the dermis compared with passive topical application.
Microneedling Protocol with GHK-Cu
| Parameter | Detail |
|---|---|
| Needle depth | 0.5-1.0 mm for facial skin |
| GHK-Cu concentration | 0.5-1% solution in clinic protocols; community reports use 1-2% (Anecdotal) |
| Application timing | Immediately after microneedling while channels are open |
| Amount | Enough to cover the treated area; gently pat in |
| Post-procedure care | No harsh actives (acids, retinoids) for 24-48 hours |
| Frequency | Every 4-6 weeks for in-clinic microneedling; home microneedling users report 1-2 sessions weekly (Anecdotal) |
| Results timeline | Faster than passive topical — improvements may be visible at 4-6 weeks |
Why Lower Concentration with Microneedling
Clinic protocols use a slightly lower concentration (0.5-1% vs. 1-2% for passive topical) because microneedling dramatically increases absorption; the community reports in the protocol table describe 1-2% with shallower home devices. A lower topical concentration with enhanced delivery may achieve similar or higher tissue levels compared to a higher concentration applied passively. Use only products made sterile for application to open skin.
Mesotherapy / Intradermal Injection
Some aesthetic practitioners administer GHK-Cu via mesotherapy — multiple shallow intradermal injections directly into the facial skin. This approach delivers the peptide directly to the dermal layer where fibroblasts reside.
Mesotherapy Protocol
| Parameter | Detail |
|---|---|
| Dose | 0.5-1 mg total, distributed across treatment area |
| Technique | Multiple 0.1 mL intradermal injections, spaced 1-2 cm apart |
| Frequency | Every 2-4 weeks |
| Sessions | 4-6 sessions for initial course |
| Maintenance | Monthly thereafter if desired |
This approach is performed exclusively by trained aesthetic physicians. It is not a self-administration route. The evidence for mesotherapy with GHK-Cu is primarily anecdotal and based on practitioner experience — no controlled trials of this specific approach have been published.
Combination Protocols
GHK-Cu + BPC-157 (Wound Healing)
| Peptide | Route | Dose | Frequency |
|---|---|---|---|
| GHK-Cu | Topical (to wound/scar) | 1-2% serum | Twice daily |
| BPC-157 | SC near wound site | 250 mcg | Once daily |
Rationale: GHK-Cu promotes collagen remodeling and gene expression for tissue repair. BPC-157 promotes angiogenesis and growth factor signaling. Together, they address both the structural reorganization and the vascular supply components of wound healing. No human study has tested this combination.
GHK-Cu + Retinoid (Anti-Aging)
| Active | Timing | Concentration |
|---|---|---|
| GHK-Cu serum | Morning | 1-2% |
| Tretinoin/retinol | Evening | Per dermatologist recommendation |
Rationale: Both stimulate collagen synthesis through distinct mechanisms. GHK-Cu acts through copper-dependent enzymatic pathways and broad gene modulation. Retinoids act through retinoid receptor activation. Using them at different times of day avoids potential formulation interactions while capturing complementary benefits.
GHK-Cu + Vitamin C + Sunscreen (Comprehensive Anti-Aging)
| Step | Product | Timing |
|---|---|---|
| 1 | GHK-Cu serum (1-2%) | Morning, after cleansing |
| 2 | Vitamin C serum (10-20% L-ascorbic acid) | Morning, 10-15 minutes after GHK-Cu |
| 3 | Broad-spectrum sunscreen (SPF 30+) | Morning, after actives absorb |
Note: Separate GHK-Cu and vitamin C by at least 10-15 minutes to minimize copper-catalyzed oxidation of ascorbic acid. Alternatively, use a vitamin C derivative (sodium ascorbyl phosphate, ascorbyl glucoside) that is less susceptible to copper-mediated oxidation.
Known and Theoretical Risks
- Topical use. Irritation, redness or contact dermatitis are possible, especially on broken or freshly treated skin. Copper can destabilise some other actives, such as low-pH vitamin C, in the same routine.
- Microneedling and mesotherapy. Pushing any product through the skin barrier turns a cosmetic into something closer to an injection. Products not made sterile for that purpose can cause infections or granulomatous reactions.
- Immunogenicity and impurities. The FDA states that compounded injectable drugs containing GHK-Cu may pose a risk of immune reactions because of aggregation and peptide-related impurities, and that human data to inform safety are limited [7].
- Research-grade product quality. Online “research peptides” are not made to pharmaceutical standards. In test purchases of semaglutide from illegal online sellers, purity was 7.7 to 14.4 percent against a 99 percent label claim, with endotoxin in every sample [8].
- Copper load. Systemic injection adds copper. In people with copper-handling disorders such as Wilson disease this is an obvious concern, and in everyone else the long-term effect is untested.
Regulatory Status
- United States (FDA). GHK-Cu is not an approved drug. On the FDA safety-risk page (content current as of 22 April 2026), GHK-Cu for injectable routes is listed among substances previously in category 2 whose nominations were withdrawn. The FDA 503A list (updated 14 May 2026) states that GHK-Cu for non-injectable routes is being added back to category 1 (“under evaluation”), and that FDA intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027 [7].
- EU and Germany. GHK-Cu is sold in cosmetics (INCI name copper tripeptide-1). It is not authorised by the EMA or the BfArM as a medicinal product, and a “research use only” label does not make an injectable product approved or tested for human use.
- Sport (WADA 2026). Not named on the 2026 Prohibited List. Section S0 covers pharmacological substances with no current approval for human therapeutic use, and S2 covers growth factor modulators affecting tissue regeneration, so athletes considering injectable use should get a ruling first [9].
How I Approach GHK-Cu When Coaching Patients
When the primary goal is facial anti-aging, I suggest starting with topical GHK-Cu at 1-2% concentration, applied twice daily, before considering injectable approaches. This is where the evidence is strongest, the safety profile is best characterized, and the cost is lowest.
For systemic goals — chronic inflammation pathways, post-surgical recovery, or systemic tissue repair — injectable GHK-Cu at 1-2 mg (most commonly 2 mg) subcutaneously, once daily or 3-5 times weekly, is the protocol most commonly used, with the caveat that the evidence base for this route is substantially thinner.
The best foundation is to combine GHK-Cu with a comprehensive skin care approach: sun protection, adequate hydration, retinoid use (if tolerated), and attention to the nutritional factors that support collagen synthesis (vitamin C, zinc, protein intake).
See a dermatologist or physician if you want measurable results for photoaging, scarring or hair loss, and ask before using copper-peptide products on broken skin, after procedures, during pregnancy, or if you have a copper-metabolism disorder. If you are being offered GHK-Cu injections, ask what product is used and who made it.
The Bottom Line
GHK-Cu dosing is route-dependent. Topical application at 1-2% concentration twice daily has the most clinical evidence and is the recommended first-line approach for skin anti-aging, although that evidence comes from small studies. Subcutaneous injection at 1-2 mg (most commonly 2 mg) once daily or 3-5 times weekly is used for systemic effects but has no published human dose-finding data and carries FDA-flagged immunogenicity and impurity concerns. Microneedling-enhanced delivery offers a middle ground with potentially faster results. Product quality, formulation stability, and concentration are as important as the peptide itself.
For the skin-specific evidence review, see GHK-Cu for Skin. For the full overview, see GHK-Cu: Copper Peptide Science.
References
- Pickart L, et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012. PMID: 22666519.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018. PMID: 29986520.
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID: 3169264.
- Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMID: 26236730.
- Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID: 16847171.
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000. PMID: 10839713.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026); Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026).
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID: 39509151.
- World Anti-Doping Agency. The 2026 Prohibited List (valid 1 January 2026), sections S0 and S2.
Disclaimer: This article is for informational and educational purposes only. It summarises doses used in research and practice; it is not a prescription or individual medical advice. GHK-Cu is sold as a cosmetic ingredient and is not approved by the FDA, the EMA or the BfArM as a medicine. Consult a qualified physician or dermatologist before pursuing any peptide therapy or procedure-based use.
